A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Abroad (travel likely)RecruitingPHASE1

Conditions

Relapsed/Refractory Multiple Myeloma · Plasma Cell Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Contact: Study coordinator (Chunrui Li) · cunrui5650@126.com · +86 13647233185

Study leads

Chunrui Li
Principal Investigator
Tongji Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Parkville, Australia

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Guangzhou, China · Tianjin, China

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Coral Gables, United States · Deerfield Beach, United States

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma · Relapse Multiple Myeloma · Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Boston, United States · Boston, United States